Back Hepatitis B

Hepatitis B

AASLD 2016: Tenofovir Alafenamide Approved for Hepatitis B, Works Well with Less Effect on Bones

Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus but causes less bone mineral loss, according to a report at the AASLD Liver Meeting this week in Boston. The U.S. Food and Drug Administration last week approved stand-alone TAF for hepatitis B treatment.

alt

Read more:

FDA Warns of HBV Reactivation Risk After Starting Hepatitis C Medications

The U.S. Food and Drug Administration (FDA) this week issued a new safety warning about the risk of hepatitis B virus (HBV) reactivation in people treated with direct-acting antivirals (DAAs) for hepatitis C. In a few cases HBV reactivation has led to serious liver problems or death. The FDA will now require a boxed warning on package labels for all DAAs. The caution applies to people who currently have chronic hepatitis B and those who previously cleared HBV spontaneously or with treatment.

alt

Read more:

Blood Test Could Help Predict Which Hepatitis B Patients Will Develop Liver Cancer

A blood test that measures a set of circulating microRNAs (miRNAs) may help identify who will develop hepatitis B virus-related hepatocellular carcinoma (HCC), a type of primary liver cancer, according to research published in the May 24 online edition of OncoTarget.

alt

Read more:

Hepatitis B Testing Should Be Done Before and During Hepatitis C Treatment

People considering treatment for hepatitis C should first be tested for hepatitis B virus (HBV) and monitored throughout therapy, as successful elimination of hepatitis C virus (HCV) can reactivate HBV and potentially worsen liver disease, according to recent updates to American and European hepatitis C treatment guidelines.

alt

Read more:

EASL 2016: Hepatitis B Treatment Linked to Colorectal and Cervical Cancer

People with hepatitis B who were treated with nucleoside/nucleotide antivirals did not have an overall higher rate of malignancies, but did show an increased incidence of colorectal and cervical cancer, underlining the need for regular screening, according to a study presented at the recent EASL International Liver Congress in Barcelona.

alt

Read more:

Viral Hepatitis Is Now A Major Global Cause of Death, Exceeding HIV and TB

Hepatitis B and C have become leading causes of death and disability worldwide, as other major communicable diseases such as HIV/AIDS, malaria, and tuberculosis (TB) have come under better control, according to an analysis published in the July 8 online edition of The Lancet.

alt

Read more:

EASL 2016: Antiviral Therapy Linked to Less Liver Cancer and Death in People with Mild Hepatitis B

Treatment with nucleoside/nucleotide antiviral therapy was associated with longer overall survival and reduced risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) for hepatitis B patients with high viral load but minimal liver inflammation -- a group generally not prioritized for treatment --according to a report presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona.

alt

Read more:

World Health Assembly Adopts Strategies for HIV, Viral Hepatitis, and STIs

The 194 member states participating in the 69th World Health Assembly, which governs the World Health Organization (WHO) in late May unanimously approved the adoption of WHO's draft global health sector strategies for management of HIV, viral hepatitis, and sexually transmitted infections (STIs) through the year 2021.

alt

Read more:

EASL 2016: Core Inhibitor NVR 3-778 Plus Pegylated Interferon Inhibits Hepatitis B Activity

NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA, and hepatitis B "e" antigen (HBeAg), showing greater activity when combined with pegylated interferon, researchers reported at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona.

alt

Read more: